Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Provides Q1/2020 Financial Results and Recent Highlights Including Initial Movantik® Revenues
Completed acquisition of Movantik ® from AstraZeneca on April 1, 2020 , and initiated U.S. promotion with net revenues of $7.3 million in April -- Launched commercial sales of Talicia ® in the U.S. in March 2020 ; Talicia ® added to Express Scripts and Prime Therapeutics formularies as an ...
View HTML
Toggle Summary RedHill Biopharma to Host First Quarter Financial Results Conference Call on May 27, 2020
TEL-AVIV, Israel and RALEIGH, N.C. , May 20, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its first quarter 2020 financial results on Wednesday, May 27, 2020 . ...
View HTML
Toggle Summary RedHill Biopharma to Present at the UBS Virtual Global Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , May 11, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Dror Ben-Asher , RedHill’s Chief Executive Officer, will present a corporate overview at the UBS ...
View HTML
Toggle Summary RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.
The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S.  -- All six analyzed moderate-to-severe COVID-19 patients treated with opaganib under compassionate use in Israel were weaned from oxygen and discharged ...
View HTML
Toggle Summary RedHill Biopharma Announces Publication of Talicia® Pivotal Phase 3 Study Results in Annals of Internal Medicine
Talicia ® is approved by the U.S. FDA and promoted by RedHill’s U.S. sales force -- Abstract discussing Talicia pharmacokinetics and exposure-response presented as ePoster at Digestive Disease Week ® (DDW) 2020 TEL-AVIV, Israel and RALEIGH, N.C. , May 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma ...
View HTML
Toggle Summary RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary
Talicia ® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies --- H. pylori bacterial infection is a Group 1 carcinogen and the strongest risk factor ...
View HTML
Toggle Summary Six COVID-19 Patients Treated with RedHill’s Opaganib Under Compassionate Use Show Objective Clinical Improvement
Preliminary data in moderate-to-severe COVID-19 patients treated with opaganib show measurable clinical improvement in all six patients analyzed, including decreased requirement for supplemental oxygenation, higher lymphocyte counts and decreased CRP  -- Five of the six patients have been weaned ...
View HTML
Toggle Summary RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19
RedHill is pursuing both RHB-107 and opaganib as potential treatments for COVID-19 TEL-AVIV, Israel and RALEIGH, N.C. , April 20, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered ...
View HTML
Toggle Summary IND for COVID-19 with Opaganib Submitted to the FDA by RedHill Biopharma
Proposed study intended to evaluate the safety and efficacy of opaganib in up to 60 patients hospitalized with positive SARS-CoV-2 infection and pneumonia in the U.S. -- Opaganib’s unique mechanism of action has both anti-viral and anti-inflammatory activities, targeting a critical host factor, ...
View HTML
Toggle Summary Additional Update on COVID-19 Compassionate Use with Opaganib in Israel Provided by RedHill Biopharma
All five patients have shown an improved CRP, with four of the five patients also demonstrating measurable clinical improvement, including required supplemental oxygenation and higher lymphocyte counts -- Opaganib was administered to all five patients in addition to standard-of-care, including ...
View HTML